Journal of Animal and Veterinary Advances

Year: 2011
Volume: 10
Issue: 8
Page No. 1032 - 1036

Study on the Resistance of Extended Spectrum β-Lactamases

Authors : Chun-Hui Zhang, Xiao-Gen Zhang, Yong-Shu Shen and Jian-Hua Wang

Abstract: The multi-drug resistance of bacteria is a serious threat to the treatment of clinical infectious diseases; Escherichia coli (E. coli) possess plasmid-encoded Extended Spectrum β-Lactamases (ESBLs) that confer multi-drug resistance. In order to overcome this kind of resistance, some experiments were done in this study. In this study for the clinic pathogenic E. coli, ESBLs genetype were detected with PCR and for the induced E. coli, the plasmid elimination effects of several plasmid-curing agents to ESBLs were investigated using SDS as a control. Results showed that the bacteria producing ESBLs were amplified TEM type ESBLs fully, two strains were amplified both TEM type ESBLs and SHV type ESBLs, only one strain was amplified both TEM type ESBLs and CTX type ESBLs. And to the induced E. coli C83845-y, the elimination rate of chlorpromazine, hydrochloride, diazepam, norfloxacin and ciprofloxacin was 14.53, 13.50, 14.59, 8.43 and 8.23%, respectively, the elimination rate of SDS was 11.05%, blank control was 0.05% to induce E. coli C83907-y, the elimination rate of chlorpromazine, hydrochloride, diazepam, norfloxacin and ciprofloxacin was 11.25, 12.23, 13.51, 9.91 and 9.03%, respectively, the elimination rate of SDS was 10.72%, blank control was 0.05%. These results indicated that ESBLs-positive E. coli in Henan have transmitted resistant gene plasmids among different bacteria, the tricyclic-psychotropic drugs were more effective at eliminating the ESBL-resistant plasmid. This study provides insight into strategies for overcoming the resistance conferred by ESBLs.

How to cite this article:

Chun-Hui Zhang, Xiao-Gen Zhang, Yong-Shu Shen and Jian-Hua Wang, 2011. Study on the Resistance of Extended Spectrum β-Lactamases. Journal of Animal and Veterinary Advances, 10: 1032-1036.

Design and power by Medwell Web Development Team. © Medwell Publishing 2022 All Rights Reserved